KineMed Enters Into Collaboration With Bristol-Myers Squibb
EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. a translational and personalized medicine development company, announced today a two-year collaboration with Bristol-Myers Squibb (NYSE: BMY) in the area of Alzheimer's disease and other neurodegenerative conditions. KineMed brings a proprietary translational and personalized medicine platform to identify and characterize novel biomarkers in cerebrospinal fluid (CSF) to facilitate development of promising new Bristol-Myers Squibb drugs for the treatment of Alzheimer's disease.
The Collaboration will apply KineMed's stable isotope technology to identify novel biomarkers that can be used to assess the extent and treatment of Alzheimer's disease.
"Bristol-Myers Squibb is committed to helping patients prevail over serious diseases through personalized medicine and KineMed has a unique approach to identifying biomarkers for neurodegenerative diseases. We value KineMed's expertise in this area and look forward to working together in the fight against neurodegenerative diseases," said Francis Cuss, M.D., Senior Vice President, Discovery and Exploratory Clinical Research, Bristol-Myers Squibb.
"We are very enthusiastic about working with Bristol-Myers Squibb as we believe our expertise and platform are most powerful when applied in the context of important drug R&D programs," Robert B. Stein, M.D., Ph.D., KineMed's CEO said.
About KineMed, Inc.
KineMed, a privately held biotechnology company based in Emeryville, CA, is a leader in translational and personalized medicine. KineMed uses the administration of stable (non-radioactive) isotopes to provide "high-definition" pharmacological measurements of disease activity and drug effects across a wide range of therapy areas, including diseases of the nervous system, metabolic and cardiovascular disease, cancer, inflammation, and musculoskeletal diseases. KineMed is developing a small, high-quality pipeline of its own in-licensed compounds.